47 rue de Paradis, 75010 Paris,France
01 42 46 50 86
info@vaincrealzheimer.org
ESPACE CHERCHEURS
PRESSE
ESPACE NOTAIRES

FAIRE UN DON
Fondation Vaincre Alzheimer Fondation Vaincre Alzheimer
  • LA FONDATION
    • Notre histoire
    • Nos missions >
      • Financement de la recherche
        • Soutenir la recherche d’excellence
        • Soutenir les jeunes chercheurs
        • Financement du don du cerveau
        • Nos projets financés
      • Soutien au personnel soignant
      • Sensibilisation
    • Notre organisation
    • Nos comptes
    • Nos emplois
    • Nos brochures
  • ALZHEIMER
    • Comprendre la maladie
    • Découverte de la maladie
    • Alzheimer en chiffres
    • Les stades
    • Les symptômes
    • Les causes
    • Le diagnostic
    • Les traitements
    • La forme héréditaire
    • La fin de vie
    • Glossaire
  • MALADIES APPARENTÉES
    • La maladie à Corps de Lewy
    • La démence fronto-temporale
    • La démence vasculaire
  • AVOIR UN PROCHE MALADE
    • La vie au quotidien –
      • Communiquer avec le malade
      • Les repas et refus de manger
      • La toilette du malade
      • Aide à l’habillage
      • Activités et participation aux tâches quotidiennes
    • Les troubles du comportement –
      • Agressivité
      • Troubles du sommeil
      • Déambulation & Fugue
    • Sécuriser le domicile
    • Conduite automobile & Alzheimer
    • Les aidants familiaux –
      • Gestion du stress de l’aidant
    • Aides matérielles et financières
    • Mesures de protection juridique
    • Expliquer Alzheimer aux enfants
  • PRÉVENTION
    • Comment prévenir ? >
      • Agir sur les facteurs de risque
      • Mémoire et alimentation
      • Travailler sa mémoire
      • Mémoire et activité physique
      • Garder le contact
    • Les études scientifiques
    • La prévention secondaire
  • AGIR
    • Devenir donateur >
      • Impôt sur le revenu
      • IFI
    • Organiser une collecte
    • Devenir ambassadeur
    • Journée mondiale Alzheimer >
      • JMA 2020
    • Giving Tuesday
    • Legs, donations et assurances-vie
    • Partenariat
  • ACTUALITÉS

PROJECTS SUPPORTED FOR 2017

You can read the descriptions and results of each research project on Alzheimer’s disease funded by Fondation Vaincre Alzheimer.

Drapeau anglais sélectionné
Drapeau français

Prof. Edith Heard

CNRS, Institut Curie, Paris

Epigenetic dysregulations of gene dosage in the ageing brain, involvement in AD

PROJECT SUMMARY

During ageing, chromatin undergoes a progressive epigenetic drift and a global loss of transcriptional silencing. Epigenetic erosion or dysregulation might lead to aberrant expression patterns (e.g. APP overexpression) during ageing, and more generally to the onset of AD. We propose to explore epigenetic mechanisms underlying changes in gene dosage during the process of brain ageing that could be implicated in AD, using recent and innovative approaches. The study will assess changes in chromatin accessibility and gene expression during ageing (in mouse), and linked to AD (human post-mortem AD samples). Mechanisms will be investigated in vitro with CRISPR Cas9-derived KO on potential targets.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Epigenetic mechanisms are suspected to be implicated in AD, but very little is known so far, as it is a recent field with technical challenges. During ageing (the predominant risk in AD), epigenetic mechanisms can become globally dysregulated. This may lead to aberrant expression of dosage sensitive genes such as APP, and to sporadic AD onset. Based on the long standing expertise of the Heard lab in epigenetics, we will address the question of epigenetic changes affecting the ageing brain and their implications in AD. The modulation of the relevant epigenetic mechanisms for example in aberrant mono/biallelic expression could also represent a therapeutic perspective.

January 1st, 2018 – December 31th, 2019 (2 years)

100 000 €

Dr. Devrim KILINC

INSERM, Institut Pasteur de Lille

Role of Pyk2/p53 Pathway in Synaptic Failure due to Localized Aβ Treatment

PROJECT SUMMARY

Pyk2 was identified as a genetic risk factor of Alzheimer’s disease (AD); however, its role in synaptic plasticity/failure is not fully understood, delaying the development of potential therapies. Using microfluidic primary neuron culture, live-cell imaging, and classical biochemisty, we aim to dissect the role of Pyk2 and the related p53 signaling pathway in synapse maturation and maintenance, and to determine if and how Pyk2 signaling modulates the effects of Aβ at pre- and/or post-synaptic levels. We also aim to screen a panel of shRNA/inhibitory molecules focused on Pyk2/p53 pathway for protecting synapses from Aβ toxicity using a novel assay system to identify potential drug targets.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

This project will determine the roles of Pyk2/p53 signaling in Aβ toxicity in primary neurons, via systematic interrogation of developmental and synapse plasticity-related read-outs at pre- and post-synaptic levels. Deciphering these mechanisms will advance our understanding of AD pathophysiology and help us identify potential therapeutic targets focused on Pyk2 and p53. The proposed project is relevant and timely, considering the emerging roles of the focal adhesion pathway (in which Pyk2 participates) in synaptic plasticity and the emerging, non-apoptotic roles of p53 in the development of the nervous system.

January 1st, 2018 – December 31th, 2019 (2 years)

40 000 €

Dr Pierre Lafaye

CNRS, Institut Pasteur, Paris

Towards amyloid plaques and tangles imaging with nanobodies

PROJECT SUMMARY

In vivo detection of amyloidß (Aß) deposits and tau neurofibrillary tangles is critical for the early diagnosis of Alzheimer’s disease (AD). Detection of these lesions using PET ligands is a burgeoning field of research still hampered by concerns about spatial resolution, sensitivity and specificity. MRI is a seducing alternative to PET imaging and we propose to develop MRI-compliant and nanobody-based imaging probes that target either Aß or tau moieties. This project is based on robust preliminary results on in vivo imaging of plaques and tangles with fluorescent nanobodies. Our aim is now to reach the in vivo MRI step using new nanobody-based contrast agents.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

Being able to detect AD brain lesions by MRI remains a challenge as, to date, all developed MRI probes do not spontaneously cross the blood-brain barrier (BBB). We recently showed that camelids single-chain antibodies (VHH region or nanobodies) targeted against Aß or tau can cross the BBB in different AD mouse models, diffuse in vivo in brain parenchyma and accumulate in plaques and tangles. We then demonstrated that these nanobodies can be conjugated to MR contrast agents and we plan to use these conjugates for the in vivo detection of AD brain lesions.

January 1st, 2018 – December 31th, 2019 (2 years)

100 000 €

Dr Isabelle LE BER

INSERM, Institut du Cerveau et de la Moelle, Paris

RNAs as diagnosis tools in FrontoTemporal Lobar Degeneration

PROJECT SUMMARY

FrontoTemporal Lobar Degeneration (FTLD) are degenerative dementias related to Alzheimer’s Disease (AD). The clinical, genetic and pathological heterogeneity of FTLD can lead, at onset, to confuse it with psychiatric disorders or AD. New biomarkers remain to be discovered to improve FTLD diagnosis. Two of the three proteins aggregated in familial and sporadic FTLD are linked to RNA biogenesis (mRNA, microRNA, lncRNA…). We propose to offer to living patients a new and precise way to improve FTLD diagnosis at onset, predict the pathology, follow the disease progression and ultimately to monitor future therapeutic trials, by using a set of carefully selected miRNA as biomarkers.

RELEVANCE OF PROPOSED RESEARCH TO ALZHEIMER’S DISEASE

FTLD is a degenerative dementia related to AD that leads to progressive behavioral deterioration and language disorders as AD. FTLD is not only the most common form of presenile dementia after AD, but also the leading type of early onset dementia. FTLD and AD also overlap at molecular level. Misfolded Tau is aggregated in AD as well as in 30% of FTLD (FTLD-TAU). Otherwise, neuronal TDP43 aggregates are found in 50-60% of remaining FTLDs (FTLD-TDP) as well as in 20-55% of AD. Thus FTLD is considered related to AD and despite new FTLD diagnosis criteria, their sensitivity and specificity are still insufficient, leading to often confuse FTLD with AD at onset.

January 1st, 2018 – December 31th, 2019 (2 years)

100 000 €

Twitter
Facebook

Recevez toutes les informations sur nos subventions, bourses et conférences en souscrivant à notre newsletter.

S’ABONNER

Projets Financés

  • Projets 2020
  • Projets 2019
  • Projets 2018
  • Projets 2017
  • Projets 2016
  • Projets 2015
  • Projets 2014
  • Projets 2013
  • Projets 2012
  • Projets 2011
  • Projets 2010
  • Projets 2009
  • Projets 2008
  • Projets 2007
  • Projets 2006
  • Projets 2005

Espace Chercheur

  • Appel à Candidature
  • DIU MA2
  • Comité Scientifique Européen
  • Projets Financés
  • Bourses de Voyage
  • Bourses de Formation
  • Bourses de M2 Recherche
  • Calendrier des Conférences

S'ABONNER À LA NEWSLETTER
CHERCHEUR
S'INSCRIRE

Fondation Vaincre Alzheimer

Créée en 2005, la Fondation Vaincre Alzheimer est une Fondation Reconnue d'Utilité Publique.
Depuis 2005, la Fondation s’est fixé pour missions le financement de la recherche scientifique de qualité et la sensibilisation du public à travers l’information sur la maladie. Elle soutient également le don de cerveau pour la recherche et la formation des médecins pour une meilleure prise en charge des personnes malades.

Nos coordonnées

Fondation Vaincre Alzheimerinfo@vaincrealzheimer.org0142465086
47 rue de ParadisPARIS75010

Menu

  • Accueil
  • La Fondation Vaincre Alzheimer
  • La maladie d’Alzheimer
  • Les maladies apparentées
  • Actualités

Nous contacter

Merci,
Votre message a bien été envoyé.

Envoyer
Catégorie juridique : 9220 – Association déclarée - SIRET : 483 041 315 00043
©Fondation Vaincre Alzheimer 2020 | Tous droits réservés  Crédits  Mentions Légales  Plan du site Politique de confidentialité  Politique des Cookies
Si nous utilisons des cookies et retenons des données anonymes, c’est pour nous aider à mieux faire notre travail de mesure d’audience et à vous proposer des annonces qui vous correspondent. Nous vous permettons également de partager nos publications sur les réseaux sociaux directement depuis notre site, pour cela ils ont besoin de déposer des cookies sur votre terminal.J'accepte toutJe refuse toutJe veux en savoir plus